Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives DOI Creative Commons
Elina Khattab,

Michaelia Kyriakou,

Elena Leonidou

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(1), С. 134 - 134

Опубликована: Янв. 20, 2025

Diabetes mellitus (DM) is a multifaceted disorder with pandemic spread and remarkable burden of cardiovascular mortality morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development cardiac dysfunction, which accompanied by heart failure (HF) symptoms in absence obvious reasons like ischemic disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have proposed, including metabolic disorders (e.g., glycation products), oxidative stress, low-grade inflammation, mitochondrial etc., should guide new therapeutic strategies. Up to now, HF treatment not differed between patients without diabetes, limits expected benefits despite high risk former group. However, DBCM may require different management, prioritize anti-diabetic medications testing other novel therapies. This review aims appraise challenges prospectives individualized pharmaceutical therapy for DBCM.

Язык: Английский

Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives DOI Creative Commons
Elina Khattab,

Michaelia Kyriakou,

Elena Leonidou

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(1), С. 134 - 134

Опубликована: Янв. 20, 2025

Diabetes mellitus (DM) is a multifaceted disorder with pandemic spread and remarkable burden of cardiovascular mortality morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development cardiac dysfunction, which accompanied by heart failure (HF) symptoms in absence obvious reasons like ischemic disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have proposed, including metabolic disorders (e.g., glycation products), oxidative stress, low-grade inflammation, mitochondrial etc., should guide new therapeutic strategies. Up to now, HF treatment not differed between patients without diabetes, limits expected benefits despite high risk former group. However, DBCM may require different management, prioritize anti-diabetic medications testing other novel therapies. This review aims appraise challenges prospectives individualized pharmaceutical therapy for DBCM.

Язык: Английский

Процитировано

0